Neo-Polycin HC (Neomycin/Bacit/P-Myx/Hydrocort) Patent Expiration, LOE Window & CMS Spending

Neo-Polycin HC (Neomycin/Bacit/P-Myx/Hydrocort) by Perrigo/Padagis: Off-Patent Genericized (AB Competition), 0 AB generics, $814 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPerrigo/Padagis
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$814
2024 Medicare Part D Spend$0
2024 Medicaid Spend$814
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Perrigo across sibling Meru public-data platforms.